Blackhill Capital’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.7M | Sell |
275,364
-5,200
| -2% | -$303K | 0.86% | 11 |
|
|
2025
Q4 | $15.1M | Hold |
280,564
| – | – | 0.78% | 11 |
|
|
2025
Q3 | $12.7M | Sell |
280,564
-700
| -0.2% | -$32.7K | 0.63% | 11 |
|
|
2025
Q2 | $13M | Sell |
281,264
-3,000
| -1% | -$147K | 0.75% | 11 |
|
|
2025
Q1 | $17.3M | Buy |
284,264
+61,100
| +27% | +$3.56M | 1.01% | 10 |
|
|
2024
Q4 | $12.6M | Buy |
223,164
+8,700
| +4% | +$486K | 0.65% | 11 |
|
|
2024
Q3 | $11.1M | Hold |
214,464
| – | – | 0.64% | 12 |
|
|
2024
Q2 | $8.91M | Sell |
214,464
-100,000
| -32% | -$4.47M | 0.55% | 14 |
|
|
2024
Q1 | $17.1M | Sell |
314,464
-56,800
| -15% | -$2.89M | 0.98% | 11 |
|
|
2023
Q4 | $19M | Sell |
371,264
-28,600
| -7% | -$1.5M | 1.53% | 10 |
|
|
2023
Q3 | $23.2M | Sell |
399,864
-10,400
| -3% | -$637K | 2.24% | 8 |
|
|
2023
Q2 | $26.2M | Sell |
410,264
-27,000
| -6% | -$1.81M | 2.82% | 8 |
|
|
2023
Q1 | $30.3M | Sell |
437,264
-3,600
| -0.8% | -$254K | 3.38% | 7 |
|
|
2022
Q4 | $31.7M | Buy |
440,864
+23,800
| +6% | +$1.79M | 3.68% | 6 |
|
|
2022
Q3 | $29.6M | Sell |
417,064
-12,100
| -3% | -$878K | 3.52% | 5 |
|
|
2022
Q2 | $33M | Sell |
429,164
-1,600
| -0.4% | -$122K | 3.83% | 7 |
|
|
2022
Q1 | $31.5M | Hold |
430,764
| – | – | 2.99% | 7 |
|
|
2021
Q4 | $26.9M | Buy |
430,764
+3,800
| +0.9% | +$223K | 2.3% | 8 |
|
|
2021
Q3 | $25.3M | Hold |
426,964
| – | – | 2.19% | 9 |
|
|
2021
Q2 | $28.5M | Hold |
426,964
| – | – | 2.6% | 7 |
|
|
2021
Q1 | $27M | Sell |
426,964
-2,000
| -0.5% | -$124K | 2.35% | 7 |
|
|
2020
Q4 | $26.6M | Buy |
428,964
+800
| +0.2% | +$49.2K | 3.21% | 6 |
|
|
2020
Q3 | $25.8M | Buy |
428,164
+3,000
| +0.7% | +$181K | 3.49% | 5 |
|
|
2020
Q2 | $25M | Sell |
425,164
-1,800
| -0.4% | -$108K | 3.68% | 6 |
|
|
2020
Q1 | $23.8M | Sell |
426,964
-2,000
| -0.5% | -$122K | 4.95% | 4 |
|
|
2019
Q4 | $27.5M | Buy |
428,964
+30,800
| +8% | +$1.76M | 4.02% | 5 |
|
|
2019
Q3 | $20.2M | Sell |
398,164
-49,381
| -11% | -$2.32M | 3.19% | 7 |
|
|
2019
Q2 | $20.3M | Buy |
447,545
+21,400
| +5% | +$997K | 3.27% | 7 |
|
|
2019
Q1 | $20.3M | Sell |
426,145
-9,100
| -2% | -$453K | 3.49% | 7 |
|
|
2018
Q4 | $22.6M | Sell |
435,245
-1,700
| -0.4% | -$91.3K | 4.33% | 5 |
|
|
2018
Q3 | $27.1M | Hold |
436,945
| – | – | 4.39% | 3 |
|
|
2018
Q2 | $24.2M | Sell |
436,945
-14,250
| -3% | -$770K | 4.3% | 3 |
|
|
2018
Q1 | $28.5M | Sell |
451,195
-15,000
| -3% | -$965K | 5.32% | 3 |
|
|
2017
Q4 | $28.6M | Hold |
466,195
| – | – | 5.16% | 2 |
|
|
2017
Q3 | $29.7M | Sell |
466,195
-2,130
| -0.5% | -$124K | 5.58% | 2 |
|
|
2017
Q2 | $26.1M | Sell |
468,325
-7,800
| -2% | -$424K | 5% | 2 |
|
|
2017
Q1 | $25.9M | Buy |
476,125
+24,023
| +5% | +$1.32M | 4.78% | 3 |
|
|
2016
Q4 | $26.4M | Sell |
452,102
-16,425
| -4% | -$898K | 5.01% | 3 |
|
|
2016
Q3 | $25.3M | Buy |
468,527
+3,055
| +0.7% | +$196K | 4.21% | 2 |
|
|
2016
Q2 | $34.2M | Hold |
465,472
| – | – | 5.55% | 2 |
|
|
2016
Q1 | $29.7M | Buy |
465,472
+2,400
| +0.5% | +$151K | 4.87% | 2 |
|
|
2015
Q4 | $31.9M | Sell |
463,072
-7,180
| -2% | -$474K | 4.96% | 2 |
|
|
2015
Q3 | $27.8M | Buy |
470,252
+7,100
| +2% | +$450K | 3.75% | 3 |
|
|
2015
Q2 | $30.8M | Buy |
463,152
+8,000
| +2% | +$527K | 3.72% | 3 |
|
|
2015
Q1 | $29.4M | Buy |
+455,152
| New | +$28.5M | 3.58% | 3 |
|
Other funds holding BMY
VCM
VPM
Blackhill Capital's BMY Position: Q1 2026 in Review
Blackhill Capital reduced its Bristol-Myers Squibb (BMY) stake by 1.9% in Q1 2026, selling an estimated $303K and leaving 275,364 shares worth $16.7M. The position accounts for 0.86% of the portfolio, ranked #11.
Blackhill Capital first reported a position in BMY in Q1 2015 and has held it in 45 quarters since. The position peaked at $34.2M in Q2 2016. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Blackhill Capital held 275,364 shares of Bristol-Myers Squibb worth $16.7M as of Q1 2026.
- Blackhill Capital sold 5,200 Bristol-Myers Squibb shares in Q1 2026, an estimated $303K.
- Bristol-Myers Squibb made up 0.86% of Blackhill Capital's portfolio in Q1 2026, its #11 holding.
- Blackhill Capital first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 45 quarters since.
- Blackhill Capital's Bristol-Myers Squibb position peaked at $34.2M in Q2 2016.
- 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Blackhill Capital's 13F filing for Q1 2026, filed 14 May 2026.